DXB (Going onto phase 3 trial results)
This Company is seriously undervalued compared to other ASX biotech juniors.
BOT - MC = $186 Million.
BIT - MC = $78 Million
IMU - MC = $300 Million
DXB - MC = $63 Million with $20 million cash in the bank and potentially several more partnership agreements pending over the coming months.
thanks to @kellybs
